



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/592953/2016

European Medicines Agency decision

P/0273/2016

of 5 October 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody (EMA-001864-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0273/2016

of 5 October 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody (EMA-001864-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Dyax Corp. on 23 November 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 August 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Dyax Corp., 55 Network Drive, 01803 – Burlington, MA, United States.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/379019/2016
London, 19 August 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001864-PIP01-15

Scope of the application

Active substance(s):

Recombinant, CHO cell expressed, fully human IgG1, kappa light chain, monoclonal antibody

Condition(s):

Prevention of hereditary angioedema attacks

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Dyax Corp.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Dyax Corp. submitted for agreement to the European Medicines Agency on 23 November 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 January 2016.

Supplementary information was provided by the applicant on 27 May 2016. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of hereditary angioedema attacks.

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Prevention of hereditary angioedema attacks

2.1.1. Indication(s) targeted by the PIP

Prevention of angioedema attacks in patients with Types I or II hereditary angioedema.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

| Area | Number of measures | Description |
|-------------------------|--------------------|-----------------|
| Quality-related studies | 0 | Not applicable. |
| Non-clinical studies | 0 | Not applicable. |

| Area | Number of measures | Description |
|---|--------------------|--|
| Clinical studies | 3 | <p>Study 1</p> <p>Double-blind, randomised, multiple dose, placebo controlled trial to evaluate pharmacokinetics, safety, efficacy of DX-2930 in children from 12 to less than 18 years of age for Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE).</p> <p>Study 2</p> <p>Open-Label Study to Evaluate the Long-Term Safety and activity of DX-2930 in children from 12 to less than 18 years of age for Prevention Against Acute Attacks of Hereditary Angioedema (HAE).</p> <p>Study 3</p> <p>Open label trial to evaluate pharmacokinetics, safety and activity of DX-2930 in children from 2 to less than 12 years of age for Prevention Against Acute Attacks of Hereditary Angioedema (HAE).</p> |
| Extrapolation, modelling and simulation studies | 2 | <p>Study 4</p> <p>Modelling and simulation study to evaluate the use of DX-2930 in the Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in children from 2 to less than 18 years.</p> <p>Study 5</p> <p>Extrapolation study, to evaluate the use of of DX-2930 in the Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in children from 2 to less than 18 years.</p> |
| Other studies | 0 | Not applicable. |
| Other measures | 0 | Not applicable. |

3. Follow-up, completion and deferral of PIP

| | |
|---|------------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By December 2020 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |